NSE · ALIVUS.NS
Alivus Life Sciences Limited
₹1,426.50+₹29.10 (+2.08%)
Alivus Life Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 4.9% below the high.
Loading market information…
NSE · BLUEJET.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:02 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Blue Jet Healthcare Limited’s quoted price sits in the upper half of its reported 52-week range, 26.27% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Blue Jet Healthcare Limited’s forward annual dividend is ₹1.20 per share, paid annual. The forward yield is 0.24% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Blue Jet Healthcare Limited’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of ₹4.36. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Blue Jet Healthcare Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Blue Jet Healthcare Ltd. is a company that focuses on the manufacturing and supply of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), which are critical components for the pharmaceutical and healthcare sectors. Its product offerings include integrated intermediates used in contrast media, saccharin and its associated salts, and a range of specialized pharmaceutical intermediates and APIs. The company also delivers comprehensive contract development and manufacturing (CDMO/CMO) and development services. Founded in 1968, Blue Jet Healthcare is headquartered in Thane, India, and maintains a broad international operational footprint across countries such as India, Norway, the United States, Sweden, Italy, and Spain.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 14, 2025 | ₹6.30+11.5% vs estimate | ₹3.40B+8.62% vs estimate |
|---|
| Q3 2025 | Jan 29, 2025 | ₹5.70+39.02% vs estimate | ₹3.18B+13.29% vs estimate |
|---|
| Q2 2025 | Oct 29, 2024 | ₹3.36+5.0% vs estimate | ₹2.08B-8.78% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,426.50+₹29.10 (+2.08%)
Alivus Life Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 4.9% below the high.
₹448.65-₹32.70 (-6.79%)
Cohance Lifesciences Limited’s quoted price sits in the lower half of its reported 52-week range, 43.79% below the high.
₹924.70-₹21.30 (-2.25%)
Jubilant Pharmova Limited’s quoted price sits in the lower half of its reported 52-week range, 21.87% below the high.
₹782.65-₹4.90 (-0.62%)
NATCO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 36.2% below the high.
₹1,248.30+₹17.70 (+1.44%)
Concord Biotech Limited’s quoted price sits in the lower half of its reported 52-week range, 22.67% below the high.
₹846.80-₹22.50 (-2.59%)
Supriya Lifescience Limited’s quoted price sits in the upper half of its reported 52-week range, 21.95% below the high.
₹113.35-₹5.96 (-5.0%)
Morepen Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 24.78% below the high.
₹513.55+₹27.75 (+5.71%)
SMS Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 2.29% below the high.
